PT  - Journal Article
AU  - Chun, Jerold
AU  - Kihara, Yasuyuki
AU  - Jonnalagadda, Deepa
AU  - Blaho, Victoria A.
DP  - 2019
TI  - Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders
TA  - Annual Review of Pharmacology and Toxicology,
VI  - 59
IP  - Volume 59, 2019
PG  - 149-170
AID - 10.1146/annurev-pharmtox-010818-021358
SO  - Annual Review of Pharmacology and Toxicology 2019;59(1):149-170
AB  - Fingolimod (FTY720, Gilenya) was the first US Food and Drug Administration–approved oral therapy for relapsing forms of multiple sclerosis (MS). Research on modified fungal metabolites converged with basic science studies that had identified lysophospholipid (LP) sphingosine 1-phosphate (S1P) receptors, providing mechanistic insights on fingolimod while validating LP receptors as drug _targets. Mechanism of action (MOA) studies identified receptor-mediated processes involving the immune system and the central nervous system (CNS). These dual actions represent a more general theme for S1P and likely other LP receptor modulators. Fingolimod's direct CNS activities likely contribute to its efficacy in MS, with particular relevance to treating progressive disease stages and forms that involve neurodegeneration. The evolving understanding of fingolimod's MOA has provided strategies for developing next-generation compounds with superior attributes, suggesting new ways to _target S1P as well as other LP receptor modulators for novel therapeutics in the CNS and other organ systems.,
4099- https://www.annualreviews.org
4100- https://www.annualreviews.org/content/journals/10.1146/annurev-pharmtox-010818-021358

  <script>parent.window.postMessage('ixistenz.url:https://www.annualreviews.org/content/journals/10.1146/annurev-pharmtox-010818-021358/cite/medline', '*'); </script> <div id='browserdiffcontainer' style='position: fixed; right: 10px; top: 10vh; min-width: 60px;  border: 1px solid white; background: rgb(251, 189, 0);; opacity: 0.9; font-family: helvetica, arial, sans serif;  font-size: 12px; z-index: 20001; padding-bottom: 20px;'><div onclick="toggle('browserdiffcontainerlist'); return false;" style='background: rgb(151, 89, 0);; color: white; '><strong>&nbsp; <span class='glyphicon glyphicon-minus'></span> NODES</strong></div><div id='browserdiffcontainerlist' style='padding-left: 10px; padding-right: 5px; max-height: 50vh; overflow: auto; '><div><a href='#diffid3547' style='color: white;' onClick="parent.window.postMessage('ixistenz.opendiff:3547', '*');; return false;" style='text-decoration: none; '>mac </a> <a style='color: white;' href='#diffid3547'><sup>2</sup></a></div><div><a href='#diffid3546' style='color: white;' onClick="parent.window.postMessage('ixistenz.opendiff:3546', '*');; return false;" style='text-decoration: none; '>os </a> <a style='color: white;' href='#diffid3546'><sup>5</sup></a></div></div></div>
<script>
function toggle( divname ) {
  var x = document.getElementById( divname );
  if (x.style.display === 'none') {
    x.style.display = 'block';
  } else {
    x.style.display = 'none';
  }
} </script>